- Conditions
- Diabetic Retinopathy, Macular Edema
- Interventions
- aflibercept
- Drug
- Lead sponsor
- Rishi Singh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1321–1344
of 11,344
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Persistent Atrial Fibrillation
- Interventions
- Phase 1: FARAPULSE Ablation System, Phase 2: FARAPULSE Ablation System
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 669 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 32 more
- Conditions
- Infrainguinal Peripheral Arterial Disease
- Interventions
- Chocolate PTA Balloon Angioplasty, Standard PTA Balloon Angioplasty
- Device
- Lead sponsor
- TriReme Medical, LLC
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Colorectal Cancer
- Interventions
- Open laparotomy and rectal resection, Laparoscopic-assisted rectal resection
- Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2019
- U.S. locations
- 35
- States / cities
- Scottsdale, Arizona • Concord, California • Los Angeles, California + 29 more
- Conditions
- Arthritis
- Interventions
- Blood Draws for Serum Titers
- Other
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 9 Years to 26 Years · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Cleveland, Ohio
- Conditions
- Obesity
- Interventions
- S-2367 Placebo, S-2367 800 mg, S-2367 1600 mg, Reduced Calorie Diet
- Drug · Other
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 724 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 38
- States / cities
- Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 35 more
- Conditions
- Invasive Mechanical Ventilation
- Interventions
- Artificial Intelligence-based Decision support
- Other
- Lead sponsor
- Technische Universität Dresden
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 318,542 participants
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Epilepsy, Epilepsy (Treatment Refractory)
- Interventions
- Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system)
- Device
- Lead sponsor
- Epiminder America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 19 more
- Conditions
- Meniscus Tear
- Interventions
- AM3101, Saline Placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Cleveland, Ohio • Portland, Oregon
- Conditions
- Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia, IDH2 Gene Mutation, Myelodysplastic Syndrome With Excess Blasts, Recurrent High Risk Myelodysplastic Syndrome, Refractory High Risk Myelodysplastic Syndrome
- Interventions
- Azacitidine, Enasidenib, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Cleveland, Ohio • Houston, Texas
- Conditions
- Bipolar Disorder, Mania
- Interventions
- Lithium (LI), Divalproex (DV)
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 7
- States / cities
- Flowood, Mississippi • White Plains, New York • Durham, North Carolina + 4 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- albiglutide, placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 310
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 250 more
- Conditions
- Cystic Fibrosis, Lung Infection, Cystic Fibrosis Pulmonary Exacerbation
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Denver, Colorado + 7 more
- Conditions
- Postoperative Pain, Inguinal Hernia
- Interventions
- Opioids, No opioids
- Drug · Other
- Lead sponsor
- Clayton Petro
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 904 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Fountain Valley, California • Royal Oak, Michigan • Cleveland, Ohio + 3 more
- Conditions
- Glioblastoma
- Interventions
- NICO Myriad and Tissue Preservation System (TPS)
- Device
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, Daratumumab/rHuPH20
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2040
- U.S. locations
- 837
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 526 more
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Detroit, Michigan • Cleveland, Ohio + 2 more
- Conditions
- Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC), Gastroenteropancreatic NEC (GEP NEC), NEC of the Bladder, Other DLL3 Expressing epNEC
- Interventions
- [212Pb]Pb-MP0712, [203Pb]Pb-MP0712
- Drug · Other
- Lead sponsor
- Molecular Partners AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 8
- States / cities
- Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Liver Transplantation
- Interventions
- Tacrolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Everolimus (reduced tacrolimus), Everolimus (tacrolimus elimination), Corticosteroids
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 719 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 28
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 20 more
- Conditions
- Aortic Aneurysm, Abdominal
- Interventions
- Endurant Stent Graft System
- Device
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 24
- States / cities
- Los Angeles, California • Stanford, California • New Haven, Connecticut + 20 more
- Conditions
- Hypertension
- Interventions
- metoprolol succinate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 30
- States / cities
- Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 27 more
- Conditions
- Vasomotor Symptoms
- Interventions
- desvenlafaxine succinate sustained release, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 55
- States / cities
- Tucson, Arizona • Beverly Hills, California • Encinitas, California + 44 more
- Conditions
- Clear Cell Renal Cell Carcinoma (ccRCC)
- Interventions
- BMS-986527, Nivolumab, Cabozantinib
- Drug
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Basking Ridge, New Jersey • New York, New York + 3 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- GLPG1690, Placebo
- Drug
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 42 more